Link to Full Article

Pharma partner has an exclusive option to a global, royalty bearing licence

Cambridge, UK., 13 February 2020: Arecor Ltd (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that it has signed a further collaboration agreement with a top five pharmaceutical company. The pharmaceutical partner will fund the feasibility study and has an exclusive option to a global royalty bearing licence to the new formulation and Arecor’s associated Intellectual Property.

Under this exclusive agreement, Arecor will use its proprietary technology platform Arestat™ to develop a stable and novel liquid formulation of a proprietary product in a ready-to-administer (RTA) infusion bag.  RTA medicines have the potential to significantly enhance patient care whilst reducing associated healthcare costs by providing safe, stable and easy to use products for healthcare professionals

Arestat™ is a world leading, innovative and proprietary formulation technology platform which significantly enhances the properties of approved therapeutic proteins and peptides. Arestat™ has the unique potential to deliver superior reformulations of existing product which would otherwise not be possible.

Sarah Howell, Chief Executive Officer of Arecor, said: “This is the second RTA collaboration that we have announced in recent weeks involving our proprietary technology platform Arestat™. It is a further project for an existing pharmaceutical partner which demonstrates the value of our technology and expertise together with the strength of our commercial relationships”.


For more information, please contact:
Arecor Limited
Dr Sarah Howell, Chief Executive Officer
Tel: +44 (0) 1223 426060
Susan Lowther, Chief Financial Officer
Tel: +44 (0) 1223 426060
Mo PR Advisory
Mo Noonan
Mob: +44 (0) 7876 444977

Notes to Editors

About Arecor (

Arecor Limited is a biopharmaceutical company transforming patient care by bringing innovative medicines to market. Through the enhancement of existing medicines using our Arestat™ technology, we are developing a broad portfolio of therapies as part of our proprietary pipeline and through partnerships with leading pharmaceutical and biotech companies. Our treatments for people living with chronic disease are designed to simplify patient care and improve medication adherence.

For further details please see our website,